Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

NVAX boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Novavax has seen some interesting price action recently; the stock is up 3.9% over the ...

According to TipRanks.com, Werber is a 4-star analyst with an average return of 7.6% and a 49.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical ...

Novavax (NVAX) smashed its Q1 2025 earnings today. The stock rocketed 33% in pre-market trading after the company reported a stunning $518 million profit for Q1 2025. This marks a complete turnaround ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...